Risk for venous thromboembolism associated with postmenopausal hormone use

Risk for venous thromboembolism associated with postmenopausal hormone use—Pretest (optional)

The editors of Sexuality, Reproduction & Menopause would like insight into your current knowledge of venous thromboembolism risk with hormone therapy. Your answers to these questions are anonymous and are not linked to your name or CME posttest score.

1) Which one of the following best describes the role of aspirin in reducing risk of coronary events and VTE in postmenopausal women on ET or EPT?
81 mg of aspirin daily reduces the risk of CHD and VTE.
100 mg of aspirin every other day reduces the risk of CHD and VTE.
325 mg of aspirin every other day reduces the risk of CHD and VTE.
Aspirin is not effective in decreasing CHD or VTE in older women.
Aspirin is not effective in decreasing CHD or VTE.

2) In the WHI, hormone therapy was clearly shown to increase the risk of VTE in which of the following thrombophilic disorders?
MTHR mutation
Antithrombin 3
Factor V Leiden
von Willebrand disease
Factor VIII deficiency

3) Patients with Factor V Leiden mutations have
Similar risks of VTE with oral and transcutaneous estrogens
No increased risk of VTE with transcutaneous estrogens
An increased risk of VTE with transcutaneous estrogen
No increased risk of VTE without estrogen therapy
No increased risk of VTE with estrogen and aspirin therapy

Thank you for your time. When you submit the survey, you will return to "Issues in postmenopausal hormone therapy: Risk for venous thromboembolism associated with postmenopausal hormone use (Part 2 of 3)."